Tvtx approval status

Travere Therapeutics (TVTX) has received FDA approval for its drug FILSPARI (Sparsentan) for the treatment of kidney disease, IgA nephropathy. The approval was granted under the Accelerated Approval pathway, and the FDA approval event type was PDUFA Date, with the approval date being September 5, 2024. This represents a significant milestone for TVTX, as it marks the first FDA approval for the company.